Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEL15U)

Drug Name

FK-143 Drug Info

Synonyms

FK-143; Fk 143; CHEMBL25083; 163136-03-6; 4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]indol-1-yl]butyric acid; 4-[3-[3-(bis[4-isobutylphenyl)methylamino]benzoyl]indol-1-yl]butyric acid; SCHEMBL3504489; AC1L435G; CTK0H5706; DTXSID80167524; LACIBZRFAYFTOV-UHFFFAOYSA-N; BDBM50057477; 1H-Indole-1-butanoicacid, 3-[3-[[bis[4-(2-methylpropyl)phenyl]methyl]amino]benzoyl]-; 4-[3-[3-[bis[4-(2-methylpropyl)phenyl]methylamino]benzoyl]indol-1-yl]butanoic acid

Indication

Disease Entry	ICD 11	Status	REF
Prostate disease	GA91	Phase 2	[1]

Cross-matching ID

PubChem CID: 178077
CAS Number: CAS 163136-03-6
TTD Drug ID: DMEL15U

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Finasteride	DMWV3TZ	Baldness, male pattern		Approved	[3]
Dutasteride	DMQ4TJK	Benign prostatic hyperplasia	GA90	Approved	[3]
Polyestradiol Phosphate	DM0PMGJ	Prostate cancer	2C82.0	Approved	[4]
Azelaic Acid	DMHVL0J	Acne vulgaris	ED80	Approved	[5]
Dutasteride + tamsulosin	DM6P8HU	Benign prostatic hyperplasia	GA90	Phase 3	[6]
Epristeride	DM35T1O	Hirsutism	ED72	Phase 3	[7]
Turosteride	DMW7PFS	Prostate disease	GA91	Phase 2	[8]
IZONSTERIDE	DM3KXMG	Hirsutism	ED72	Phase 1/2	[9]
ONO-3805	DM1RKWV	Prostate disease	GA91	Discontinued in Phase 3	[10]
CS-891B	DM17I8O	Alopecia	ED70	Discontinued in Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)	TT2A0DR	S5A1_HUMAN; S5A2_HUMAN; PORED_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003112)
2	FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (1) In vitro effects on human and animal prostatic enzymes. J Steroid Biochem Mol Biol. 1995 Apr;52(4):357-63.
3	The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988 Nov;119(5):627-32.
6	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
7	Discovery of a novel hybrid from finasteride and epristeride as 5alpha-reductase inhibitor. Bioorg Med Chem Lett. 2011 Jan 1;21(1):475-8.
8	Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat. J Steroid Biochem Mol Biol. 1993 Nov;46(5):549-55.
9	Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible... Urology. 2004 Jan;63(1):114-9.
10	Significant role of 5 alpha-reductase on feedback effects of androgen in rat anterior pituitary cells demonstrated with a nonsteroidal 5 alpha-redu... J Androl. 1994 Nov-Dec;15(6):521-7.
11	The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles. Eur J Dermatol. 2000 Dec;10(8):593-5.